'Universal' influenza vaccine development underway in Europe

December 4, 2013
Development of a 'universal' influenza vaccine underway in Europe
Credit: Shutterstock

A newly launched European project is set to take a major step toward the development of a universal flu vaccine. It aims to counter the emergence of new strains and seasonal epidemics.

The viral infection usually strikes in colder months with being responsible for around 3 - 5 million cases of severe illness and 250,000 to 500,000 deaths worldwide.

Due to its rapid spread particularly among high risk population groups, remains a serious public health problem. To date, the most effective way to prevent the disease or severe symptoms is annual vaccination but current vaccines only offer limited protection against evolving strains of the infection.

To overcome these weaknesses, a public-private partnership comprising seven renowned organisations from Europe joined forces under the EDUFLUVAC project to develop a broad-spectrum, long-lasting against influenza.

EDUFLUVAC launched into action only a month ago and aims to take a novel approach by 'educating' the immune system to cross-recognise common regions within multiple strains.

'Developing a universal has become a global health priority for preventing the spread of the virus and the emergence of new strains, and we are convinced that EDUFLUVAC will be a major step forward towards achieving this goal', says Othmar Engelhardt, principal investigator at the National Institute for Biological Standards and Control, United Kingdom.'

The research team expects to achieve better protection against epidemic influenza through the development of a vaccine that would not only offer the tremendous advantage of eliminating the need for a seasonal vaccine every year but could also reduce the need for costly annual vaccination campaigns.

Odile Leroy, Executive Director of the European Vaccine Initiative and coordinator of EDUFLUVAC, says: 'Low and middle-income countries currently have minimal programmes. Thus, the development of a vaccine that elicits broad long-lasting defence would facilitate vaccination campaigns and confer protection against influenza in hitherto untargeted groups with limited health care'.

The four-year project is coordinated by the European Vaccine Initiative headquartered in Germany and was awarded a grant of EUR 4.6 million in EU funding.

More information: Project factsheet: cordis.europa.eu/projects/rcn/110279_en.html

Related Stories

FDA approves first 4-in-1 flu vaccine

February 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

FDA approves H5N1 avian influenza vaccine

November 26, 2013

(HealthDay)—The U.S. Food and Drug Administration has approved the first adjuvanted vaccine for the prevention of H5N1 influenza in adults at greater-than-average risk of exposure.

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.